01/23/2025 – iQure Pharma’s iQ-007 Receives FDA Orphan Drug Designation for Dravet’s Syndrome.
iQure Pharma iQ-007 Receives Orphan Drug Status
01/23/2025 – iQure Pharma’s iQ-007 Receives FDA Orphan Drug Designation for Dravet’s Syndrome.